BIOSPECIFICS TECHNOLOGIES CORP Form 8-K June 03, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

## **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): June 1, 2011

# BIOSPECIFICS TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

#### Delaware

(State or Other Jurisdiction Of Incorporation)

#### 001-34236

(Commission File Number)

## 11-3054851

(I.R.S. Employer Identification No.)

## 35 Wilbur Street Lynbrook, NY 11563

(Address of Principal Executive Office) (Zip Code)

## 516.593.7000

(Registrant s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

## Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

## INTRODUCTORY COMMENT

Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technolo Corp.

## ITEM 8.01 OTHER EVENTS

On June 1, 2011, the Company issued a press release announcing that positive data for XIAPEX® were presented at the XVIth Annual Federation of European Societies for Surgery of the Hand Congress which took place in Oslo, Norway on May 26-28, 2011.

A press release regarding the announcement is attached hereto as Exhibit 99.1.

## ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

99.1 Press release dated June 1, 2011

# Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 2, 2011	BIOSPECIFICS TECHNOLOGIES CORP.
	(Registrant)
	/s/ Thomas L. Wegman
	Thomas L. Wegman
	President

# Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 8-K

# **EXHIBIT INDEX**

Exhibit Description
---------------------

No.

99.1 Press release dated June 1, 2011